{"id":"NCT03449134","sponsor":"Merck Sharp & Dohme LLC","briefTitle":"A Study of Gefapixant (MK-7264) in Adult Participants With Chronic Cough (MK-7264-027)","officialTitle":"A Phase 3, Randomized, Double-Blind, Placebo-Controlled, 12-Month Study to Evaluate the Efficacy and Safety of MK-7264 in Adult Participants With Chronic Cough (PN027)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2018-03-14","primaryCompletion":"2020-06-05","completion":"2020-08-17","firstPosted":"2018-02-28","resultsPosted":"2021-06-16","lastUpdate":"2021-06-16"},"enrollment":732,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Chronic Cough"],"interventions":[{"type":"DRUG","name":"Placebo","otherNames":[]},{"type":"DRUG","name":"Gefapixant","otherNames":["MK-7264"]}],"arms":[{"label":"Placebo","type":"PLACEBO_COMPARATOR"},{"label":"Gefapixant 15 mg BID","type":"EXPERIMENTAL"},{"label":"Gefapixant 45 mg BID","type":"EXPERIMENTAL"}],"summary":"The main objectives of this study will be to evaluate the efficacy of gefapixant in reducing cough frequency as measured over a 24-hour period at Week 12, and to evaluate the safety and tolerability of gefapixant. The primary hypothesis is that at least one gefapixant dose is superior to placebo in reducing coughs per hour (over 24 hours) at Week 12.","primaryOutcome":{"measure":"Model-Based Geometric Mean Ratio (GMR) of 24-hour Objective Coughs Per Hour (Week 12/Baseline)","timeFrame":"Baseline, Week 12","effectByArm":[{"arm":"Placebo","deltaMin":0.47,"sd":null},{"arm":"Gefapixant 15 mg BID","deltaMin":0.48,"sd":null},{"arm":"Gefapixant 45 mg BID","deltaMin":0.38,"sd":null}],"pValues":[{"comp":"OG000 vs OG002","p":"0.041"},{"comp":"OG000 vs OG001","p":"0.874"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":14},"locations":{"siteCount":156,"countries":["United States","Argentina","Canada","Czechia","Denmark","France","Hungary","Israel","Japan","Peru","Poland","South Korea","Spain","Taiwan","Turkey (TÃ¼rkiye)","Ukraine","United Kingdom"]},"refs":{"pmids":["35569802","35248186"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":14,"n":243},"commonTop":["Nasopharyngitis","Dysgeusia","Headache","Back pain","Bronchitis"]}}